RxDoctor Payments Data

Shelly Fizer, APRN

Family · Logan, WVNPI 1447773692

Payments from drug & device makers

$3,884in general payments, 2019–2025

Across 189 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$1K
  • Smith+Nephew$1K
  • Melinta Therapeutics, LLC$319
  • ETS Wound Care LLC$167
  • Paratek Pharmaceuticals, Inc.$143
  • Kerecis Limited$86
  • plus $300 from 10 others

What the payments were for

  • Food & beverage$3,882100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,884 in reported general payments places this provider in the 90th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$91,631
Medicare patients
100
Services billed
1,752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.24$83,236
ErtapenemErtapenem Sodium32$15,972
CeftriaxoneCeftriaxone Sodium37$1,673
Mupirocin163$1,375
SsdSilver Sulfadiazine16$855
Clindamycin Hcl66$661
Ampicillin Trihydrate20$298
Levofloxacin47$296
Doxycycline Hyclate44$273
Silver Sulfadiazine13$267
Lidocaine17$242
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$140
Fluconazole18$121
Cephalexin14$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$1,391$83,23624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,507 family providers in West Virginia.

Other family in Logan

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →